Aberrant promoter methylation of the ABCG2 gene in renal carcinoma

Molecular and Cellular Biology

Volumn 26, Issue 22, 2006, Pages 8572-8585

  To, Kenneth K W ^a   Zhan, Z ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BREAST CANCER RESISTANCE PROTEIN; DNA; HISTONE; HISTONE DEACETYLASE 1; HISTONE H3; LYSINE; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; TRANSCRIPTION FACTOR SIN3A;

ABCG2 GENE; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION MAPPING;

ATP-BINDING CASSETTE TRANSPORTERS; AZACITIDINE; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; KIDNEY NEOPLASMS; LYSINE; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33751017087     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00650-06     Document Type: Article

References (59)

1. Alleman, W. G., R. L. Tabios, G. V. Chandramouli, O. N. Aprelikova, C. Torres-Cabala, A. Mendoza, C. Rogers, N. A. Sopko, W. M. Linehan, and J. R. Vasselli. 2004. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin. Cancer Res. 10:7011-7021.
2. Allikmets, R., L. M. Schriml, A. Hutchinson, V. Romano-Spica, and M. Dean. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58:5337-5339.
3. Auriol, E., L. M. Billard, F. Magdinier, and R. Dante. 2005. Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus. Nucleic Acids Res. 33:4243-4254.
4. Bailey-Dell, K. J., B. Kassel, L. A. Doyle, and D. D. Ross. 2001. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520:234-241.
5. Baylin, S., and T. H. Bestor. 2002. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1:299-305.
6. Baylin, S. B., and J. G. Herman. 2000. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168-174.
7. Bird, A. P., and A. P. Wolffe. 1999. Methylation-induced repression-belts, braces, and chromatin. Cell 99:451-454.
8. Breedveld, P., N. Zelcer, D. Pluim, O. Sonmezer, M. M. Tibben, J. H. Beijnen, A. H. Schinkel, O. van Tellingen, P. Borst, and J. H. Schellens. 2004. Mechanism of the pharmacokinetic interaction between methrotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64:5804-5811.
9. Bunting, K. D. 2002. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20:11-20.
10. Cameron, E. E., K. E. Bachman, S. Myohanen, J. G. Herman, and S. B. Baylin. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-107.
11. Coffee, B., F. Zhang, S. T. Warren, and D. Reines. 1999. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22:98-101.
12. Delaval K., and R. Feil. 2004. Epigenetic regulation of mammalian genomic imprinting. Curr. Opin. Genet. Dev. 14:188-195.
13. Dell, G., M. Charalambous, and A. Ward. 2001. In vitro methylation of specific regions in recombinant DNA constructs by excision and religation. Methods Mol. Biol. 181:251-258.
14. Doyle, L. A., and D. D. Ross. 2003. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
15. Doyle, L. A., W. Yang, L. V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi, and D. D. Ross. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95:15665-15670.
16. Ee, P. L., S. Kamalakaran, D. Tonetti, X. He, D. D. Ross, and W. T. Beck. 2004. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res. 64:1247-1251.
17. Egger, G., G. Liang, A. Aparicio, and P. A. Jones. 2004. Epigenetics in human disease and prospects for epigenetics therapy. Nature 429:457-463.
18. Feinberg, A. P., S. Rainier, and M. R. DeBaun. 1995. Genomic imprinting, DNA methylation, and cancer. J. Natl. Cancer Inst. Monogr. 1995:21-26.
19. Fujita, N., S. Takebayashi, K. Okumura, S. Kudo, T. Chiba, H. Saya, and M. Nakao. 1999. Methylation-mediated transcriptional silencing in euchromatin by methyl-CpG binding protein MBD1 isoforms. Mol. Cell. Biol. 19:6415-6426.
20. Fuks, F. 2005. DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 15:490-495.
21. Fuks, F., P. J. Hurd, D. Wolf, X. Nan, A. P. Bird, and T. Kouzarides. 2003. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278:4035-4040.
22. Geiman, T. M., U. T. Sankpal, A. K. Robertson, Y. Chen, M. Mazumdar, J. T. Heale, J. A. Schmiesing, W. Kim, K. Yokomori, Y. Zhao, and K. D. Robertson. 2004. Isolation and characterization of a novel DNA methyl-transferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery. Nucleic Acids Res. 32:2716-2729.
23. Herman, J. G., F. Latif, Y. Weng, M. I. Lerman, B. Zbar, S. Liu, D. Samid, D. S. Duan, J. R. Gnarra, and W. M. Linehan. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91:9700-9704.
24. Ifergan, I., A. Shafran, G. Jansen, J. H. Hooijberg, G. L. Scheffer, and Y. G. Assaraf. 2004. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. J. Biol. Chem. 279:25527-25534.
25. Jhaveri, M. S., C. Wagner, and J. B. Trepel. 2001. Impact of extracellular folate levels on global gene expression. Mol. Pharmacol. 60:1288-1295.
26. Jones, P. A., and S. B. Baylin. 2002. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3:415-428.
27. Jones, P. A., and P. W. Laird. 1999. Cancer epigenetics comes of age. Nat. Genet. 21:163-167.
28. Jones, P. L., G. J. Veenstra, P. A. Wade, D. Vermaak, S. U. Kass, and N. Landsberger. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:187-191.
29. Jonker, J. W., J. W. Smit, R. F. Brinkhuis, M. Maliepaard, J. H. Beijnen, J. H. Schellens, and A. H. Schinkel. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92:1651-1656.
30. Kass, S. U., D. Pruss, and A. P. Wolffe. 1997. How does DNA methylation repress transcription? Trends Genet. 13:444-449.
31. Kouzarides, T. 2002. Histone methylation in transcriptional control. Curr. Opin. Genet. Dev. 12:198-209.
32. Krishnamurthy, P., D. D. Ross, T. Nakanishi, K. Bailey-Dell, S. Zhou, K. E. Mercer, B. Sarkadi, B. P. Sorrentino, and J. D. Schuetz. 2004. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279:24218-24225.
33. Latif, F., K. Tory, J. Gnarra, M. Yao, F. M. Duh, M. L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, and L. Geil. 1993. Identification of the von Hippel Lindau disease tumor suppressor gene. Science 260:1317-1320.
34. Li, E. 2002. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3:662-673.
35. Li, L.-C., and R. Dahiya. 2002. MethPrimer designing primers for methylation PCRs. Bioinformatics 18:1427-1431.
36. Maliepaard, M., G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van De Vijverqq, R. J. Scheper, and J. H. Schellens. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458-3464.
37. Meehan, R. R., J. D. Lewis, and A. P. Bird. 1992. Characterization of MeCP2, a vertebate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20:5085-5092.
38. Meehan, R. R., J. D. Lewis, S. McKay, E. L. Kleiner, and A. P. Bird. 1989. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell 58:499-507.
39. Miyake, K., L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. Brangi, L. Greenberger, M. Dean, T. Fojo, and S. E. Bates. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistance cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8-13.
40. Momparler, R. L. 2003. Cancer epigenetics. Oncogene 22:6479-6483.
41. Nan, X., H. H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N. Eisenman, and A. Bird. 1998. Transcriptional repression by the methyl CpG binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389.
42. Ng, H. H., P. Jeppesen, and A. Bird. 2000. Active repression of methylated genes by the chromosomal protein MBD1. Mol. Cell. Biol. 20:1394-1406.
43. Ng, H. H., Y. Zhang, B. Hendrich, C. A. Johnson, B. M. Turner, and H. Erdjument-Bromage. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23:58-61.
44. Nguyen, C. T., D. J. Weisenberger, M. Velicescu, F. A. Gonzales, J. C. Lin, G. Liang, and P. A. Jones. 2002. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 62:6456-6461.
45. 1NK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett. 187:69-75.
46. Robey, R. W., Y. Honjo, A. van de Laar, K. Miyake, J. T. Regis, T. Litman, and S. E. Bates. 2001. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys. Acta 1512:171-182.
47. Skehan, P., R. Stornet, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. Warren, H. Bokbosch, S. Kenny, and M. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112.
48. Snape, A. 2000. MBDs mediate methylation, deacetylation and transcriptional repression. Trends Gehet. 16:20.
49. Snowden, A. W., P. D. Gregory, C. C. Case, and C. O. Pabo. 2002. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr. Biol. 12:2159-2166.
50. Soengas, M. S., P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J. G. Herman, W. L. Gerald, and Y. A. Lazebnik. 2001. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211.
51. Stancheva, I. 2005. Caught in conspiracy: cooperation between DNA methylation and histone H3K9 methylation in the establishment and maintenance of heterochromatin. Biochem. Cell Biol. 83:385-395.
52. Strahl, B. D., and C. D. Allis. 2000. The language of covalent histone modifications. Nature 403:41-45.
53. Suzuki, H., E. Gabrielson, W. Chen, R. Anbazhagan, M. Van Engeland, M. P. Weijenberg, J. G. Herman, and S. B. Baylin. 2002. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31:141-149.
54. Takai, D., and P. A. Jones. 2003. The CpG Island Searcher: a new www resource. In Silico Biol. 3:0021. (CpG Island Searcher; www.uscnorris.com /cpgislands/cpg.cgi.)
55. Van Herwaarden, A. E., J. W. Jonker, E. Wagenaar, R. F. Brinkhuis, J. H. Schellend, J. H. Beijnen, and A. H. Schinkel. 2003. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63:6447-6452.
56. Volk, E. L., K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider. 2000. Methrotrexate cross-resistance in a mitoxantrone- selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 60:3514-3521.
57. Wade, P. A. 2001. Methyl CpG-binding proteins and transcriptional repression. Bioassays 23:1131-1137.
58. Zhong, C. X., and M. J. Mass. 2001. Both hypomethylation and hypermethylation of DNA associated with arsenite exposure in cultures of human cells identified by methylation-sensitive arbitrarily-primed PCR. Toxicol. Lett. 122:223-234.
59. Zhou, S., J. D. Schuetz, K. D. Bunting, A. M. Colapietro, J. Sampath, J. J. Morris, I. Lagutina, G. C. Grosveld, M. Osawa, H. Nakauchi, and B. P. Sorrentino. 2001. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7:1028-1034.